iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Emcure Pharma Soars 34.8% on NSE at Close

10 Jul 2024 , 03:39 PM

Emcure Pharmaceuticals shares made a spectacular start on July 10, closing at ₹1,359.15, a 34.8% premium to the issue price of ₹1,008.

This comes after a successful Initial Public Offering (IPO), which sparked tremendous investor interest. Emcure’s IPO, which ran from July 3 to July 5, was a book-built offering for ₹1,952.03 Crore.

QIBs dominated the bidding, subscribing 92.94 times their permitted quota, while non-institutional investors purchased 42.57 times the reserved fraction. Employees of Emcure Pharmaceuticals expressed substantial interest, bidding 7.9 times their permitted quota, while retail investors purchased 6.33 times.

The IPO includes a new issue of 0.79 Crore shares worth ₹800 Crores and an offer for sale of 1.14 Crore shares worth ₹1,152.03 Crores. The price band for the IPO was fixed at ₹960 to ₹1,008 per share.

The allotment of shares was finalised on July 8, and Emcure Pharma shares were scheduled to be listed on the BSE and NSE on July 10.

The IPO is being managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited, with Link Intime India Private Ltd serving as the registrar.

Emcure Pharmaceuticals, headquartered in India, specialises in the discovery, production, and global marketing of pharmaceutical products across a variety of therapeutic areas. Emcure’s pharmaceutical range comprises orals, injectables, and biotherapeutics, and the company operates in more than 70 countries throughout the world.

The company has 13 manufacturing facilities in India and produces a variety of dosage forms, including oral solids, oral liquids, and injectables, both liposomal and lyophilized. These facilities are also capable of producing biotherapeutics and complicated active pharmaceutical ingredients (APIs), including chiral molecules, iron molecules, and cytotoxic compounds.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Emcure Pharma
  • IPO
  • listing
  • NSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.